Published in Ann Oncol on September 01, 1999
A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer. Br J Cancer (2002) 0.89
Kinetic targeting of pegylated liposomal doxorubicin: a new approach to reduce toxicity during chemotherapy (CARL-trial). BMC Cancer (2011) 0.80
A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer. Br J Cancer (2002) 0.78
New approaches in the management of advanced breast cancer - role of combination treatment with liposomal doxorubicin. Breast Cancer (Dove Med Press) (2009) 0.75
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol (2013) 9.68
The mesothelial keratins: a new family of cytoskeletal proteins identified in cultured mesothelial cells and nonkeratinizing epithelia. Cell (1982) 4.17
Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol (1999) 4.12
Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol (2001) 3.23
Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol (1998) 2.55
Primary care for survivors of breast cancer. N Engl J Med (2000) 2.39
Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol (1999) 2.23
Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res (2000) 2.17
American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol (1999) 2.03
Differentiation of Klebsiella-Enterobacter (Aerobacter)-Serratia by biochemical tests and antibiotic susceptibility. Appl Microbiol (1968) 1.89
Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol (2001) 1.89
Weight gain in women diagnosed with breast cancer. J Am Diet Assoc (1997) 1.87
Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. J Natl Cancer Inst Monogr (2001) 1.84
Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. J Clin Oncol (1998) 1.66
Sildenafil for iatrogenic serotonergic antidepressant medication-induced sexual dysfunction in 4 patients. J Clin Psychiatry (1999) 1.62
First-line Herceptin monotherapy in metastatic breast cancer. Oncology (2001) 1.60
Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep (1979) 1.50
Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med (1993) 1.45
Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol (2000) 1.41
Enhanced antibody response of mice to polyinosinic-polycytidylic acid by antithymocyte serum and its age-dependent loss in NZB-W mice. J Immunol (1973) 1.40
Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy. Am J Clin Nutr (1997) 1.37
Complications of axillary lymph node dissection for carcinoma of the breast: a report based on a patient survey. Cancer (1998) 1.34
Immunofluorescence studies on thymocytotoxic antibody from New Zealand Black mice. J Immunol (1974) 1.31
Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat (2011) 1.29
Germline E-cadherin mutations in familial lobular breast cancer. J Med Genet (2007) 1.28
Views of female breast cancer patients who donated biologic samples regarding storage and use of samples for genetic research. Clin Genet (2006) 1.27
Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol (2005) 1.25
Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol (2013) 1.24
Osteogenic protein versus autologous interbody arthrodesis in the sheep thoracic spine. A comparative endoscopic study using the Bagby and Kuslich interbody fusion device. Spine (Phila Pa 1976) (1999) 1.24
NCCN Practice Guidelines for Breast Cancer. Oncology (Williston Park) (2000) 1.22
Why women gain weight with adjuvant chemotherapy for breast cancer. J Clin Oncol (1993) 1.21
Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer. Breast Cancer Res Treat (2009) 1.19
Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells. Br J Cancer (2009) 1.18
Menopausal-type symptoms in young breast cancer survivors. Ann Oncol (2006) 1.15
Nodular fasciitis in the parotid region of a child. Head Neck (1998) 1.14
The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol (2001) 1.10
Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease. Neuropsychologia (2005) 1.10
Rocky Mountain spotted fever complicated by gangrene: report of six cases and review. Clin Infect Dis (1993) 1.07
Improved survival in advanced Hodgkin's disease with the use of combined modality therapy. Int J Radiat Oncol Biol Phys (1990) 1.06
Knowledge, satisfaction, and perceived cancer risk among women diagnosed with ductal carcinoma in situ. J Womens Health Gend Based Med (2001) 1.05
High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst (1992) 1.04
The effects of rigid spinal instrumentation and solid bony fusion on spinal kinematics. A posterolateral spinal arthrodesis model. Spine (Phila Pa 1976) (1998) 1.04
Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2. J Clin Oncol (1999) 1.03
Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. Clin Pharmacol Ther (1991) 1.03
The impact of sharing results of a randomized breast cancer clinical trial with study participants. Breast Cancer Res Treat (2008) 1.03
Cancer pain survey: patient-centered issues in control. J Pain Symptom Manage (1998) 1.03
The bovine papilloma virus E1 protein has ATPase activity essential to viral DNA replication and efficient transformation in cells. Virology (1994) 1.02
High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Am J Med (1980) 1.02
A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181. Cancer (2000) 1.01
Sildenafil for women patients with antidepressant-induced sexual dysfunction. Psychiatr Serv (1999) 1.01
Combination chemotherapy with adriamycin-cyclophosphamide for advanced ovarian carcinoma. Cancer (1980) 1.00
First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report. Eur J Cancer (2001) 0.99
Short-chain fatty acids inhibit intestinal trefoil factor gene expression in colon cancer cells. Am J Physiol (1998) 0.99
The distal biceps tendon. Two potential mechanisms involved in its rupture: arterial supply and mechanical impingement. J Shoulder Elbow Surg (1995) 0.99
Clinical pharmacology of cancer chemotherapy in children. Pediatr Clin North Am (1989) 0.98
The antibody response to polyinosinic polycytidylic acid. J Immunol (1973) 0.97
New modified fluorescence polarization immunoassay does not falsely elevate vancomycin concentrations in patients with end-stage renal disease. Ther Drug Monit (1998) 0.96
Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support. J Clin Oncol (1999) 0.96
Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J Clin Oncol (2001) 0.96
Attitudes of patients with metastatic breast cancer toward research biopsies. Ann Oncol (2013) 0.96
Long term sex-dependent psychoneuroendocrine effects of maternal deprivation and juvenile unpredictable stress in rats. J Neuroendocrinol (2011) 0.95
HDAC inhibitors induce transcriptional repression of high copy number genes in breast cancer through elongation blockade. Oncogene (2013) 0.94
Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes? Ann Oncol (2012) 0.94
Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children. Clin Pharmacol Ther (1989) 0.94
Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification. Br J Cancer (2012) 0.93
Intraaterial hepatic infusion and intravenous adriamycin for treatment of hepatocellular carcinoma: a clinical and pharmacology report. Cancer (1978) 0.92
Cefoxitin therapy for Mycobacterium fortuitum bacteremia with associated granulomatous hepatitis. South Med J (1984) 0.92
Static and fatigue biomechanical properties of anterior thoracolumbar instrumentation systems. A synthetic testing model. Spine (Phila Pa 1976) (1999) 0.92
Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. Ann Oncol (2011) 0.92
Does a dedicated discharge coordinator improve the quality of hospital discharge? Qual Health Care (1996) 0.91
Topical thrombin and acquired coagulation factor inhibitors: clinical spectrum and laboratory diagnosis. Am J Hematol (1994) 0.90
Corticosteroid dependence of continuous hemopoiesis in vitro with murine or human bone marrow. Haematol Blood Transfus (1981) 0.90
Mechanism of allograft rejection in New Zealand mice. II. Role of a serum factor. J Immunol (1974) 0.90
High-dose BCNU with autologous bone marrow rescue for recurrent glioblastoma multiforme. J Neurosurg (1981) 0.89
Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector. Cancer Res (2001) 0.86
Pharmacokinetic studies with recombinant cytokines. Scientific issues and practical considerations. Clin Pharmacokinet (1997) 0.86
Sodium channel density in hypomyelinated brain increased by myelin basic protein gene deletion. Nature (1991) 0.86
Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat. Br J Pharmacol (2008) 0.86
CMF revisited in the 21st century. Ann Oncol (2011) 0.85
Characterization of endogenous cytokine concentrations after high-dose chemotherapy with autologous bone marrow support. Blood (1993) 0.85
A purified diet for medaka (Oryzias latipes): refining a fish model for toxicological research. Lab Anim Sci (1992) 0.85
Inhibition of nucleic acid synthesis by the di-n-butyl ester of methotrexate. Biochem Pharmacol (1976) 0.85
In vitro proliferation of hemopoietic stem cells in long-term marrow cultures: principles in mouse applied to man. Exp Hematol (1979) 0.85
Is axillary lymph node dissection indicated for early-stage breast cancer? A decision analysis. J Clin Oncol (1999) 0.84
Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trial. Cancer Res (1992) 0.84
Hyperacusis in Williams syndrome. J Otolaryngol (2001) 0.84
Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study. Cytokine (1995) 0.84
New cytotoxic agents and schedules for advanced breast cancer. Semin Oncol (2001) 0.84
Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. Cancer Chemother Pharmacol (1998) 0.84
Autologous bone-marrow transplantation: host effects of high-dose BCNU. J Clin Oncol (1983) 0.83
Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol (2000) 0.83
Delayed pulmonary toxicity syndrome following high-dose chemotherapy and bone marrow transplantation for breast cancer. Am J Respir Crit Care Med (1998) 0.83